Anti-mutagenic and Anti-oxidant Potencies of Cetraria Aculeata (Schreb.) Fr., Cladonia Chlorophaea (Flörke ex Sommerf.) Spreng. and Cetrelia olivetorum (Nyl.) W.L. Culb. & C.F. Culb.)

Selcuk Ceker; Furkan Orhan; Selma Sezen; Medine Gulluce; Hakan Ozkan; Ali Aslan; Güleray Agar

doi:10.22037/ijpr.2018.2157

Anti-mutagenic and Anti-oxidant Potencies of Cetraria Aculeata (Schreb.) Fr., Cladonia Chlorophaea (Flörke ex Sommerf.) Spreng. and Cetrelia olivetorum (Nyl.) W.L. Culb. & C.F. Culb.)

authors:

Selcuk Ceker ^{a
, *} , Furkan Orhan ^b , Selma Sezen ^c , Medine Gulluce ^c , Hakan Ozkan ^c , Ali Aslan ^d , Güleray Agar ^c

a Agri Ibrahim Cecen University, Faculity of Pharmacy, Agri, TR-04100, Turkey.

b Agri Ibrahim Cecen University, Central Research and Application Laboratory, Agri, TR-04100, Turkey.

c Ataturk University, Faculty of Science, Department of Biology, Erzurum, TR-25240, Turkey.

d Yüzüncü Yıl University, Faculity of Pharmacy TR-65150, Turkey.

Iranian Journal of Pharmaceutical Research : IJPR: Vol.17, issue 1; 326-335

article type: Original Article

received: April , 2016

accepted: January , 2017

DOI: https://doi.org/10.22037/ijpr.2018.2157

how to cite: Ceker S, Orhan F, Sezen S, Gulluce M, Ozkan H, et al. Anti-mutagenic and Anti-oxidant Potencies of Cetraria Aculeata (Schreb.) Fr., Cladonia Chlorophaea (Flörke ex Sommerf.) Spreng. and Cetrelia olivetorum (Nyl.) W.L. Culb. & C.F. Culb.). Iran J Pharm Res. 2018;17(1):e124760. https://doi.org/10.22037/ijpr.2018.2157.

Abstract

In this study, the mutagenic and anti-mutagenic effects of methanol extract of three lichen species (Cetraria aculeata, Cladonia chlorophaea and Cetrelia olivetorum) were investigated by using E. coli-WP2, Ames-Salmonella (TA1535 and TA1537) and sister chromatid exchange (SCE) test systems. The results obtained from bacterial test systems demonstrated that methanol extracts of three lichen species have strong anti-mutagenic potencies on TA1535, TA1537 strains and to a lesser extent on E. coli-WP2 strain. The anti-oxidant level of human lymphocytes cells was determined in order to clarify the mechanism underlying the anti-mutagenic effects of these lichen species. Co-treatments of 5, 10 and 20 µg/mL concentrations of these three lichen species with AFB decreased the frequencies of SCE and the level of MDA and increased the amount of SOD, GSH and GPx which decreased by aflatoxin. The findings of this work have clearly demonstrated that Cetraria aculeata, Cladonia chlorophaea and Cetrelia olivetorum have significant anti-mutagenic effects which are thought to be partly due to the anti-oxidant activities and the interaction capability of lichen extracts with mutagen agents (Sodium azide, acridin, N-methyl-N′-nitro-N-nitrosoguanidine and aflatoxin B₁).

Keywords

Lichen extracts Anti-mutagenicity Anti-oxidant Short term tests (Ames-Salmonella E. coli-WP2 SCE)

Introduction

Lichens are slow-growing organisms and are a rich source of various biologically active substances used for many purposes. The use of lichen as food, dyes, perfume, species, fodder, and medicine are among these purposes (1, 2). Biological activities of lichens arise from their secondary metabolites. While secondary metabolites of lichen protect/ sustain the symbiotic association from various stress factors (biotic and abiotic), they also have medical applications (3). Anti-microbial (4), anti-inflammatory (5), analgesic (6), anti-viral (7), anti-proliferative (8), anti-oxidant (9-11), and cytotoxic effects (12) are among the applications of lichen secondary metabolites.

In this study, we have investigated anti-mutagenic/anti-genotoxic potential of three lichen species, [Cetraria aculeata (Schreb.) Fr., Cladonia chlorophaea (Flörke ex Sommerf.) Spreng. and Cetrelia olivetorum (Nyl.) W.L. Culb. & C.F. Culb.)]. According to the available literature, Cetrariaaculeata (CA) contains protolichesterinic and lichesterinic acid (13-15), Cladonia chlorophaea (CC) contains fumarprotocetraric, homosekikaic, imbricaric and protolichesterinic acid (16) and Cetrelia olivetorum (CO) contains atranorin, chloroatranorin, and olivetoric acid as major contents (16). To the best of our knowledge there is no study about CC and CO lichen species. On the other hand, there are several studies reporting a wide range activity of secondary metabolites of these lichen species. In this respect, Celenza et al. (17) reported anti-bacterial activity of fumarprotocetraric acid form a Chilean lichen species. Similarly, Tigre et al. (18) reported allelopathic and bio-herbicidal potential of fumarprotocetraric acid. Luo et al. (19) indicated that homosekikaic containing an edible lichen species has anti-oxidant and free radical scavenging activities. In a more recent study, anti-microbial and anti-oxidant properties of homosekikaic have been demonstrated (20). Oettl et al. (21) isolate two depsides (imbricaric and perlatolic acid) from a lichen species (Cetrelia monachorum) and demonstrated that these depsides have multi-targeting anti-inflammatory effects. The studies of lichen secondary metabolites have been performed either with content isolated from lichens or with commercial forms. For example, Backorova et al. (22) have purchased four lichen secondary metabolites (atranorin, usnic acid, parietin and gyrophoric acid) and demonstrated that usnic acid and atranorin were more effective than other compounds investigated. In a study performed with three different cancer cell lines, Kristmundsdottir et al. (23) reported that (+) -usnic acid has positive effects on all cell lines tested. Valencia-Islas et al. (24) reported that boninic acid, 2-O-methylsekikaic acid, salazinic acid, chloroatranorin, atranorin, and (+) -usnic acid have anti-oxidant activity and anti-radical potential. In another study performed with protolichesterinic acid it has been demonstrated that this compound reduce the growth of two different prostate cancer lines (25).

Taking the knowledge of the literature and the results of this study into account, it seems that the investigated lichen species have significant anti-oxidant and anti-mutagen properties. In light of the fact that the investigated lichen species did not show any genotoxic properties on the Ames-Salmonella and human lymphocytes cells, they can be considered as genotoxically safe at all tested concentrations and can be used as promising agents in order to ameliorated toxicity of sodium azide, acridin, N-methyl-N′-nitro-N-nitrosoguanidine, and aflatoxin B₁.

Experimental

Plant material

Lichen samples of CA, CC and CO were collected from Giresun province of Turkey in 2010. The samples were identified by Associate Prof. Dr. Ali ASLAN, using various flora books and papers (26-28). Vouchers were stored in the herbarium of Kazım Karabekir Education Faculty, Ataturk University (the herbarium number of CA: ATA-KKEF-1865, CC: ATA-KKEF-1866 and CO: ATA-KKEF-1876).

Table 1

Anti-mutagenicity assay results of the methanol extract of CA, CC and CO for S. tyhimurium TA1535, TA1537 and E. coli WP2uvrA bacterial tester strains

Test Items	Concentration (µg/plate)	Number of revertants
		*E. coli* *WP2uvrA***		*S. typhimurium* TA1535		*S. typhimurium* TA1537
		Mean S.E.	Inhib. %	Mean S.E.	Inhib. %	Mean S.E.	Inhib. %
Mutagen agent (positive control)	MNNG (1), NaN₃(1) 9-AA(40)	285.500 07.15		548.00 12.26ö		311.00 07.16ö
DMSO^** (µL/plate)	100	28.00 01.23		12.50 01.00		11.00 01.20
CA	2	258.50 04.50	-	361.50 08.45	34.03	292.00 03.40	-
	4	259.50 03.78	-	376.50 07.29	31.38	229.00 05.27	26.36
	6	241.00 04.08	-	387.50 10.13	29.28	220.00 04.50	29.26
	8	219.50 05.60	-	408.50 08.10	25.45	214.00 05.63	31.18
	10	261.00 02.23	-	431.00 06.82	21.35	184.00 04.30	40.83
Mutagen agent (positive control)		561.00 01.47		548.00 01.36		347.00 00.85
DMSO^** (µL/plate)	100	23.00 02.04		12.50 01.14		11.00 01.26
CC	2	350.00 02.70	37.61	371.00 08.40	32.29	251.00 05.48	27.66
	4	362.50 05.00	35.38	397.50 05.45	27.46	243.50 04.27	29.82
	6	396.50 04.10	29.32	331.00 10.00	39.59	203.50 05.16	41.35
	8	334.00 03.06	40.46	408.50 04.22	25.45	198.00 03.34	42.93
	10	372.00 03.88	33.68	441.00 06.45	-	203.50 05.30	41.35
Mutagen agent (positive control)		458.00 04.00		487.00 01.75		347.00 00.74
DMSO^** (µL/plate)	100	33.00 03.17		12.50 01.06		11.00 01.23
CO	2	355.50 02.50	22.37	319.00 07.18	34.49	212.00 04.40	38.91
	4	368.00 02.18	-	302.50 10.00	37.88	255.00 02.51	26.51
	6	389.50 05.42	-	341.50 08.20	29.87	253.00 02.57	27.08
	8	386.50 06.00	-	389.00 04.50	20.12	188.00 01.90	45.82
	10	376.50 02.60	-	353.50 06.27	27.41	163.50 04.35	52.88

P <0,05,

MNNG, NaN₃ and 9-AA were used as positive controls for E. coli WP2uvrA, S. typhimurium TA1535 and TA1537 strains, respectively. 10% DMSO (dimethylsulfoxide) was used as negative control. CA: Cetrariaaculeata, CC:Cladonia chlorophae and CO: Cetralia olivetorum. S.E:Standard error.

Table 2

SCE frequency in human blood lymphocytes treated with AFB and CA, CC and CO.

	Concentrations	Metaphase	Range of SCEs	SCEs/Cell	SCE/Cell ± S.E
Test Items
Control		80	2-8	421	6.91 ± 0.82^a
AFB	5 µM	80	6-14	476	9.60 ± 0.21^e
CA	10 µg/mL	80	3-9	406	6.96 ± 0.13^a
AFB + CA	5 µM + 5 µg/mL	80	5-9	508	8.40 ± 0.10^cd
AFB +CA	5 µM + 10 µg/mL	80	3-10	471	7.93 ± 0.32^bc
AFB + CA	5 µM + 20 µg/mL	80	4-10	446	7.43 ± 0.17^b
Control		80	4-7	382	6.36 ± 0.78^a
AFB	5 µM	80	3-13	546	9.10 ± 0.14^e
CC	10 µg/mL	80	4-9	412	6.86 ± 0.12^ab
AFB + CC	5 µM + 5 µg/mL	80	3-11	491	8.18 ± 0.21^d
AFB + CC	5 µM + 10 µg/mL	80	4-10	460	7.63 ± 0.19^c
AFB + CC	5 µM + 20 µg/mL	80	5-10	448	7.46 ± 0.22^bc
Control		80	2-7	332	5.53 ± 0.67^a
AFB	5 µM	80	4-12	536	8.93 ± 0.41^e
CO	10 µg/mL	80	3-9	346	6.10 ± 0.09^a
AFB + CO	5 µM + 5 µg/mL	80	4-10	440	7.41 ± 0.33^cd
AFB + CO	5 µM + 10 µg/mL	80	3-11	400	6.66 ± 0.27^b
AFB + CO	5 µM + 20 µg/mL	80	4-9	394	6.63 ± 0.16^b

Table 3

The effects of AFB and MEL on SOD, GPX, GSH and MDA enzymes activities

Test Items	SOD (U/mL)	GPx (U/mL)	GSH (µmol/L)	MDA (nmol/mL)
Control	1.53 ± 0.22^a	1.18 ± 0.07^a	3.36 ± 0.41^a	1.30 ± 0.17^a
AFB (5 µM)	0.97 ± 0.21^d	0.46 ± 0.12^d	1.34 ± 0.12^d	4.69 ± 0.10^d
CA (10 µg/mL)	1.62 ± 0.18^a	1.42 ± 0.08^a	3.12 ± 0.13^a	2.66 ± 0.20^b
AFB (5 µM) + CA (5 µg/mL)	1.24 ± 0.08^bc	0.98 ± 0.11^b	2.67 ± 0.22^bc	5.44 ± 0. 12^d
AFB (5 µM) + CA(10 µg/mL)	1.41 ± 0.16^ab	1.08 ± 0.10^ab	2.98 ± 0.16^ab	3.73 ± 0.21^c
AFB (5 µM) + CA (20 µg/mL)	1.49 ± 0.21^a	1.57 ± 0.07^a	3.22 ± 0.18^a	3.02 ± 0.27^bc
Control	1.81 ± 0.12^a	0.89 ± 0.12^a	3.92 ± 0.20^a	3.42 ± 0.08^a
AFB (5 µM)	0.99 ± 0.43^d	0.51 ± 0.17^d	1.37 ± 0.12^d	4.81 ± 0.13^d
CC (10 µg/mL)	1.86 ± 0.22^a	1.44 ± 0.15^a	3.42 ± 0.14^a	3.73 ± 0.10^b
AFB (5 µM) + CC (5 µg/mL)	1.74 ± 0.17^a	0.77 ± 0.1^b	2.26 ± 0.19^c	5.53 ± 0.09^d
AFB (5 µM) + CC (10 µg/mL)	1.72 ± 0.10^a	0.78 ± 0.21^b	3.84 ± 0.21^a	3.97 ± 0.24^bc
AFB (5 µM) + CC (20 µg/mL)	1.71 ± 0.35^a	0.96 ± 0.07^a	3.78 ± 0.17^a	3.51 ± 0.32^a
Control	1.65 ± 0.21^a	1.38 ± 0.08^a	3.15 ± 0.20^a	2.41 ± 0.07^a
AFB (5 µM)	0.96 ± 0.20^d	0.44 ± 0.18^d	1.35 ± 0.07^d	4.72 ± 0.08^d
CO (10 µg/mL)	1.63 ± 0.18^a	1.42 ± 0.25^a	3.18 ± 0.11^a	2.98 ± 0.22^b
AFB (5 µM) + CO (5 µg/mL)	1.67 ± 0.09^a	0.80 ± 0.09^c	2.64 ± 0.23^b	2.34 ± 0.21^a
AFB (5 µM) + CO (10 µg/mL)	1.69 ± 0.36^a	0.96 ± 0.06^b	2.91 ± 0.07^ab	2.24 ± 0.19^a
AFB (5 µM) + CO (20 µg/mL)	1.68 ± 0.13^a	1.18 ± 0.11^ab	3.05 ± 0.15^a	4.60 ± 0.12^d

Preparation of methanol extracts

Air-dried and powdered lichens (20 g) were extracted with 200 mL of methanol using the Soxhlet extractor (Isopad, Heidelberg, Germany) for 48 h at a temperature not exceeding the boiling point of the solvent (29). The extract was filtered using Whatman fitler paper (no.1) and then concentrated in vacuum at 40 °C using a rotary evaporator (Buchi Labortechnic AG, Flawil, Switzerland) yielding a waxy material.

Cytogenetic analysis of sister chromatid exchange (SCE)

For the cytogenetic analysis of SCE peripheral blood lymphocytes were taken from four nonsmoking healthy donors between the ages of 22 and 25. Lymphocyte cultures were set up by adding 0.5 mL of heparinized whole blood to RPMI-1640 chromosome medium supplemented with 15% heat-inactivated fetal calf serum, 100 IU/mL streptomycin, 100 IU/mL penicillin and 2% L-glutamine. Lymphocytes were stimulated to divide by 2% phytohemagglutinin. Aflatoxin B₁ (AFB; 5 µM) and methanol extract of each lichen species (CA, CC and CO) at concentrations of 5, 10 and 20 µg/mL were added to the cultures just before incubation.

For sister chromatid exchange (SCE) demonstration, the cultures were incubated at 37 °C for 72 h and 5-bromo 2-deoxyuridine at 8 µg/mL was added at the initiation of cultures. All cultures were maintained in darkness. Afterward, 3 µg/mL of colcemide was added 90 min before harvesting to arrest the cells at metaphase. The cultures were centrifuged at 1200 rpm for 10 min. The supernatants were used for enzyme analysis. Cells were harvested and treated for 25 min at 37 °C with hypotonic solution (0.075 M KCl) and centrifuged for 10 min at 1200 rpm then fixed in a 1:3 mixture of acetic acid/methanol (vol/vol). The treatment with fixative was repeated three times. Then, the cells were spread on glass slides and air-dried in dark for 1 week. The staining of air dried slides was performed following the modified fluorescence plus 5% Giemsa method for SCE (30). The slides was irradiated with 30 W, 254 nm UV lamp at 15 cm distance in Sorensen buffer for 30 min, then incubated with 19 SSC (standard saline citrate) at 65 °C for 15 min and stained with 5% Giemsa prepared with Sorensen buffer. Thereafter, the slides were air-dried in dark for 1 week. In order to score SCE, 20 satisfactory metaphases were analyzed. For each treatment condition, well-spread second division metaphases containing 42–46 chromosomes in each cell were scored, and the values obtained were calculated as SCEs per cell.

Bacterial genotoxicity assays

Bacterial strains

Salmonella typhimurium TA1535 (ATCC^® Number: 29629), S. typhimurium TA1537 (ATCC^® Number: 29630) strains were provided by The American Type Culture Collection – Bacteria Department of Georgetown University, Washington, USA, and E. coli WP2uvrA (ATCC® Number: 49979) strain was provided by LGC standards Middlesex, UK. All strains were stored at -80 ºC. Working cultures were prepared by inoculating nutrient broth with the frozen cultures, followed by an overnight incubation at 37 ºC with gentle agitation (31).

Viability assays and determination of test concentrations

Toxic levels of the test materials towards S. typhimurium TA1535, 1537 and E. coli WP2uvrA strains were determined as described in detail elsewhere (32). These tests confirmed that there was normal growth of the background lawn, spontaneous colony numbers within the regular range, and no significant reduction in cell survival. Thus, for the concentrations and conditions reported here, no toxicity or other adverse effects were observed.

Ames-Salmonella and WP2 test systems

The bacterial mutagenicity and anti-mutagenicity assays were performed as described before (33). The known mutagens NaN₃ (in distilled water -1 µg/plate) for S. typhimurium TA1535 and 9-AA (in methanol -10 µg/plate) for S. typhimurium TA1537 were used as positive controls and 10% DMSO was used as negative control in these studies. In the mutagenicity test performed with TA1535 and TA1537 strains of S. typhimurium, 100 µL of the overnight bacterial culture, 50 µL test compounds at different concentrations (20, 40, 60, 80 and 100 µg/ /plate in 10% DMSO) and 500 µL phosphate buffer were added to 2 mL of the top agar containing 0.5 mM histidine/biotin. The mixture was poured onto minimal glucose plates. Histidine-independent revertant colonies and viable cells were scored on plates after incubation at 37 °C for 48 or 72 h. In the anti-mutagenicity test performed with the same strains, 100 µL of the overnight bacterial culture, 50 µL mutagen, 50 µL test compounds at different concentrations (20, 40, 60, 80 and 100 µg/ /plate in 10% DMSO) and 500 µL phosphate buffer were added to 2 mL of the top agar containing 0.5 mM histidine/biotin. The mixture was poured onto minimal glucose plates. Histidine independent revertant colonies and viable cells were scored on plates after incubation at 37 °C for 48 or 72 h. The procedures of mutagenicity and anti-mutagenicity assays, which are mentioned for the Salmonella assay, are all applicable to the E. coli-WP2 reverse mutation assay. The only procedural difference is the addition of limited tryptophan (0.05 mM) instead of histidine to the top agar (34). The plate incorporation method was used to assess the results of mutagenicity and anti-mutagenicity assays (33, 34). For the mutagenicity assays, the mutagenic index was calculated for each concentration, which is the average number of revertants per plate divided by the average number of revertants per plate with the negative (solvent) control. A sample was considered as mutagenic when a dose-response relationship and a two fold increase in the number of revertants with at least one concentration were observed (35). For the anti-mutagenicity assays, the inhibition rate (%) of mutagenicity was calculated by using the following equation (M: number of revertants/plate induced by mutagen alone, S0: number of spontaneous revertants, S1: number of revertants/plate induced by the extract plus the mutagen). %Inhibition = 1-[(M-S1) / (M-S0)] ×100 25–40% inhibition was defined as moderate anti-mutagenicity; 40% or more inhibition as strong anti-mutagenicity; and 25% inhibition as no anti-mutagenicity (36).

Biochemical analysis

Superoxide dismutase (SOD) assay

Cu-Zn-SOD activity of the whole blood cell culture supernatant was evaluated by the method of Sun and others (37). In the assay, 2.45 mL of assay reagent [0.3 mM xanthine, 0.6 mM Na₂EDTA, 0.15 mM nitroblue tetrazolium (NBT), 0.4 M Na₂CO₃, and 1 g/L bovine serum albumin] was combined with equal amount of protein from each experimental group (38) and 50 µL xanthine oxidase was added to initiate the reaction. The reduction of NBT by superoxide anion radicals was determined by measuring the absorbance at 560 nm. Cu, Zn-SOD activity was expressed in units of SOD per mg protein, where 1 U was determined as the amount of enzyme causing half-maximal inhibition of NBT reduction.

Glutathion (GSH) assay

GSH levels in the whole blood cell culture supernatant were assessed according to the method described by Anderson et al. (39). In a 3 mL cuvette, 750 µL of 10 mM 5-5’-dithio-bis-2-nitrobenzoic acid (DTNB) solution (100 mM KH₂PO₄ plus 5 mM Na₂EDTA, pH 7.5 and GSH-RD, 625 U/L) was combined with equal amount of protein from each experimental group (40). To each sample 150 µL of 1.47 mM ß-NADPH was added after a 3 min incubation period at room temperature. The mixture was rapidly mixed by inversion and the rate of 5-thio-2-nitrobenzoic acid formation was measured photometrically for 2 min at 412 nm. The reference cuvette contained equal concentrations of DTNB and NADPH but no sample. Values were presented as µmol per gram protein.

Glutathione peroxidase (GPx) assay

GPx activity of the whole blood cell culture supernatant was measured by the method described by Paglia and Valentine (40). In the assay, 100 µL of 8 mM NADPH, 100 µL of 150 mM reduced GSH, 20 µL of glutathione reductase (30 units/mL), 20 µL of 0.12 M sodium azide solution and 2.65 mL of 50 mM potassium phosphate buffer (pH 7.0, 5 mM EDTA) was combined with equal amount of protein from each experimental group (38). The samples were incubated for 30 min at 37 °C.

The reaction was initiated by the addition of 100 µL of 2 mM H₂O₂ solution and the conversion of NADPH to NADP was measured photometrically for 5 min at 340 nm. The enzyme activity was expressed as units per g protein using an extinction coefficient of 6.22 × 10^-6 for NADPH at 340 nm.

Malanoaldehyde (MDA) assay

MDA levels in the whole blood cell culture supernatant were determined spectrophotometrically according to the method described by Ohkawa et al. (41). A mixture of 8.1% sodium dodecyl sulphate, 20% acetic acid and 0.9% thiobarbituric acid was combined with equal amount of protein from each experimental group (38). Distilled water was added to the mixture to make the total volume 4mL. This mixture was incubated at 95 °C for 1 h. After incubation, the samples were left to cool under cold water, 1 mL distilled water and 5 mL n-butanol/pyridine (15:1, v/v) were added to the solution and mixed thoroughly. The samples were centrifuged at 4000 rpm for 10 min. The supernatants were separated and measured at 532 nm.

The level of MDA was calculated from a standard graph made by using different concentrations (1-10 nmol) of 1, 1, 3, 3-tetramethoxypropane and was expressed as µmol of formed MDA mL of serum.

Statistical analysis

Statistical significances of the SCE frequencies were determined using a one-way ANOVA analysis followed by a high range statistical domain using Turkey’s test. A level of probability of p <0.05 was taken as indicating statistical significance. Results were expressed as mean ± S.E. All experiments were performed in three replicates and data was compared for reproducibility.

Results

According to the data obtained from the Ames-Salmonella TA1535 strain, any concentrations of three lichen extracts tested have no mutagenic property. On the other hand, the extracts of CA and CO lichen species showed anti-mutagenic activity at all concentrations, and the extract of CC showed anti-mutagenic activity at four concentrations tested. Similarly, these three lichen extracts have significant anti-mutagenic properties on Ames-Salmonella TA1537 strain. Depending on the increasing concentrations of lichen extracts, the anti-mutagenicity of lichen extracts was reduced in the TA1535 strain while it was increased in the TA1537 strain (Table 1). Interestingly, the results obtained from E. coli-WP2 test system showed that the extract of CA has no anti-mutagenicity and the other two lichen extracts (CC and CO) have anti-mutagenic potential. All results were shown in Table 1.

The other short term test performed in this study was SCE. Three lichen extracts reduced the number of SCEs and that reduction was found to be statistically significant (P <0.05). The results of SCEs were shown in Table 2.

The final analysis of these three lichen extracts was performed with human lymphocytes cells (the anti-oxidant level of human lymphocytes) in order to clarify the mechanism underlying the anti-mutagenic and anti-genotoxic potential of these lichen species. For this aim, the activities of SOD, GSH, GPx and MDA anti-oxidants of the control and experimental groups were determined. According to the data obtained from human lymphocytes, a decrease in the activities of SOD, GSH, GPx and an increase in the MDA level were observed with treatment of AFB. On the other hand, the application of AFB with different concentrations of lichen extracts increased the activities of SOD, GSH, GPx and decreased the MDA level. The results of the anti-oxidant level of human lymphocytes were represented in Table 3. The statistical analysis showed a significant difference in SOD, GSH, GPx and MDA between all treated samples with AFB and simultaneous treatment of AFB with lichen extracts (P < 0.05).

Discussion

In this study, the mutagenic and anti-mutagenic potential of three lichen species have been investigated and reported that these lichen species have no mutagenic properties, significant anti-mutagenic potentials yet. The investigated lichen species have been examined against MNNG, NaN₃, 9-AA and AFB mutation agents in the E. coli-WP2, Ames-Salmonella (TA1535, TA1537) and in human peripheral blood cells, respectively.

In the E coli WP2 test system, the compound, MNNG, was used as a mutagenic agent. This mutagenic agent shows its mutagenic properties by adding alkyl groups to the O⁶ of Guanine, thus, the formation of O⁶-methylguanine occurs. In our study, methanol extract of CC showed a significant anti-mutagenic potential at all concentrations, the methanol extract of CO showed a slight anti-mutagenic potential only at the lowest concentration and the methanol extract of CA did not show any anti-mutagenic effect in the E coli WP2 test system against MNNG mutagen agent. The anti-mutagenic activity of methanol extract of CC and CO can be attributed to the inhibitor activities of these lichen extracts on the formation of O⁶-methylguanine as mutagen agent (MNNG) leads to the formation of O⁶-methylguanine.

In the Ames test system, the compound, NaN₃, was used as a mutagenic agent for the strain of S. typhimurium TA1535 strain. The mutagenicity of this compound is to interpose through the production of an organic metabolite (L-azidoadenine) of azide compounds. The generated organic metabolite, L-azidoadenine, enters into nucleus and then interacts with DNA and originates point mutation in the genome (42). Three lichen species have no mutagenic property on S. typhimurium TA1535 strain.

The other strain of S. typhimurium used in this study was TA1537. For this strain, 9-AA was used as a mutagenic agent that is known to be a model frameshift agent (43). In the frameshift mutagenesis mechanism, 9-AA binds to DNA non-covalently by intercalation. Through this way, 9-AA induces frameshift mutations at hot spots where guanine is repeated (44). The results obtained from S. typhimurium TA1537 strain showed that these three lichen species have no mutagenic properties but anti-mutagenic properties in formation of frameshift caused by 9-AA. When we evaluate the result of the Ames test system, we can conclude that two lichen species (CA and CO) have anti-mutagenic properties at all concentrations and one lichen species (CC) has anti-mutagenic properties at four concentrations against NaN₃. Similarly, all concentrations of two lichen species (CC and CO) and four concentrations of CA have anti-mutagenicity against 9-AA. The anti-mutagenic activity of three lichen extracts may be due to their inhibition capabilities by blocking the formation of L-azidoadenine and 9-AA binding to DNA.

The third short-term test system used for the evaluation of three lichen species was the formation of SCE in human lymphocyte cells. For SCE test system AFB was used as a positive mutagen agent. AFB is one of the most potent carcinogenic/hepatogenic agents. This compound attacks cellular constitutes such as nucleophilic nitrogen, oxygen, and sulphur heteroatoms (45). When AFB is combined with bases of DNA, it generates adducts which eventually disrupts the process, growth, division, and control of cells (46). Recently, it has been documented that AFB generates micronuclei, SCE, chromosomal aberrations, breakage of chromosomal strands in bone marrow cells and formations of adducts in rodent and human cells (47). The results obtained from human lymphocyte cells demonstrated that all concentrations of CC, CO and two concentrations of CA (20 and 10 µg/mL) reduced the formation of SCE. Interestingly, the lowest concentration of CA increased the formation of SCE. Except from the lowest concentration of CA, other lichen species (CC and CO) and higher concentrations of CA prevented the formation of SCE in a dose dependent manner in human lymphocytes cells which are in accordance with the previous report (47).

On the other hand, a well-known fact is the defense system protection in which cells/organisms are protected against oxidative damage/reactive oxygen species (ROS) by enzymatic and non-enzymatic anti-oxidants. When the anti-oxidant capability of cells is exceeded by the concentration of ROS then oxidative damage endangers the cells or tissue. It is well documented that AFB reduces the level of GSH, activities of SOD and GPx, but it increases the level of MDA (48). In our study the co-treatments of AFB with each of lichen extract (CA, CC and CO) reinstated the level of MDA and the activities of enzymatic and non-enzymatic anti-oxidants (48). Since the anti-oxidants are vital in the preventions of oxidative damage caused by exogenous agents, the use of naturally occurring compounds such as lichens can protect human beings from damage caused by ROS.

Considering the properties of lichen contents in the literature and the results of this study into account, use of lichen extracts and lichen contents for medical purposes might be useful as they have potential anti-genotoxic properties. On the other hand, more studies are needed; especially clinical studies, which can improve our knowledge about lichen species and their application in related fields.

References

1.
Manojlovic NT, Vasilijec PJ, Maskovic PZ. Chemical composition and antioxidant activity of lichen Toninia candida. Braz. J. Pharmacogn. 2012;22:291-8.
2.
Rankovic B, Kosanic M, Manojlovic N, Rancic A, Stanojkovic T. Chemical composition of Hypogymnia physodes lichen and biological activities of some its major metabolites. Med. Chem. Res. 2014;23:408-16.
3.
Shukla V, Joshi GP, Rawat MSM. Lichens as a potential natural source of bioactive compounds. Phytochem. Rev. 2010;9:303-14.
4.
Manojlovic TN, Solujic S, Sukdolak S. Antimicrobial activity of an extract and anthraquinones from Caloplaca schaereri. Lichenologist. 2002;34:83-5.
5.
Tanas S, Odabasoglu F, Halici Z, Cakir A, Aygun H, Aslan A, Suleyman H. Evaluation of anti-inflammatory and antioxidant activities of Peltigera rufescens lichen species in acute and chronic inflammation models. J. Nat. Med. 2010;64:42-9. [PubMed ID: 19830512].
6.
Bugni TS, Andjelic CD, Pole AR, Rai P, Ireland CM, Barrows, LR. Biologically active components of a Papua New Guinea analgesic and antiinflammatory lichen preparation. Fitoterapia. 2009;80:270-3. [PubMed ID: 19289158].
7.
Esimone CO, Grunwald T, Nworu CS, Kuate S, Proksch P, Uberla K. Broad spectrum antiviral fractions from the lichen Ramalina farinacea (L) Ach. Chemotherapy. 2009;55:119-26. [PubMed ID: 19155620].
8.
Triggiani D, Ceccarelli D, Tiezzi A, Pisani T, Munzi S, Gaggi C, Loppi S. Antiproliferative activity of lichen extracts on murine myeloma cells. Biologia. 2009;64:59-62.
9.
Agar G, Aslan A, Sarioglu EK, Alpsoy L, Ceker S. Protective activity of the methanol extract of Usnea longissima against oxidative damage and genotoxicity caused by aflatoxin B(1) in vitro. Turk. J. Med. Sc.i. 2011;6:1043-9.
10.
Aslan A, Yazıcı K, Karagoz Y. Lichen flora of the Murgul district, Artvin, Turkey. Israel. J. Plant. Sciences. 2002;50:77-81.
11.
Aslan A, Gulluce M, Sokmen M, Adıguzel A, Sahin F, Ozkan H. Antioxidant and antimicrobial properties of the lichens Cladonia foliacea, Dermatocarporn miniatum, Evernia divaricata, Evernia prunastri and Neofuscelia pulla. Pharm. Biol. 2006;44:247-52.
12.
Manojlović N, Vasiljević P, Gritsanapan W, Supabphol R, Manojlović I. Phytochemical and antioxidant studies of Laurera benguelensis growing in Thailand. Biol. Res. 2010;43:169-76. [PubMed ID: 21031261].
13.
Turk AO, Yılmaz M, Kıvanc M, Turk H. The antimicrobial activity of extracts of the lichen Cetraria aculeata and its protolichesterinic acid constituent. Zeitschrift für Naturforschung C. 2003;58:850-4.
14.
Zeytinoglu H, Incesu Z, Ayaz Tuylu B, Turk Ozdemir A, Barutca B. Determination of genotoxic, antigenotoxic and cytotoxic potential of the extract from lichen Cetraria aculeata (Schreb) Fr in-vitro. Phytother. Res. 2008;22:118-23. [PubMed ID: 17726729].
15.
Perez-Ortega S, Fernandez-Mendoza F, Raggio J, Vivas M, Ascaso C, Sancho LG, Printzen C, de los Rios A. Extreme phenotypic variation in Cetraria aculeata (lichenized Ascomycota):adaptation or incidental modification? Ann. Bot. 2012;109:1133-48. [PubMed ID: 22451601].
16.
Culberson CF. Supplement to ‘Chemical and botanical guide to lichen products’. Brvologist. 1970;73:177-377.
17.
Celenza G, Segatore B, Setacci D, Perilli M, Brisdelli F, Bellio P, Piovano M, Juan A, Garbarino JA, Amicosante G, Nicoletti M. Antibacterial activity of selected metabolites from Chilean lichen species against methicillin-resistant staphylococci. Nat. Prod. Res. 2012;27:1528-31. [PubMed ID: 23030591].
18.
Tigre RC, Silva NH, Santos MG, Honda NK, Falcao E PS, Pereira EC. Allelopathic and bioherbicidal potential of Cladonia verticillaris on the germination and growth of Lactuca sativa. Ecotox. Environ. Safe. 2012;84:125-32.
19.
Luo H, Wei X, Yamamoto Y, Liu Y, Wang L, Jung JS, Koh YJ, Jae-Seoun H. Antioxidant activities of edible lichen Ramalina conduplicans and its free radical-scavenging constituents. Mycoscience. 2010;51:391-5.
20.
Sosida R, Goel M, Verma S, Rani A, Dureja P. Antibacterial and antioxidant activity of lichen species Ramalina roesleri. Nat. Prod. Res. 2013;27:2235-9. [PubMed ID: 23822758].
21.
Oettl SK, Gerstmeier J, Khan SY, Wiechmann K, Bauer J, Atanasov AG, Malainer C, Awad EM, Uhrin P, Heiss EH, Waltenberger B, Remias D, Breuss JM, Boustie J, Dirsch VM, Stuppner H, Werz O, Rollinger JM. Imbricaric Acid and Perlatolic Acid: Multi-Targeting Anti-Inflammatory Depsides from Cetrelia monachorum. PLoS One. 2013;8:e76929.
22.
Backorova M, Jendzeloysky R, Kello M, Backor M, Mikes J, Fedorocko P. Lichen secondary metabolites are responsible for induction of apoptosis in HT-29 and A2780 human cancer cell lines. Toxicol.In vitro. 2012;26:462-8. [PubMed ID: 22285236].
23.
Kristmundsdottir T, Jonsdottir E, O gmundsdottir HM, Ingolfsdottir K. Solubilization of poorly soluble lichen metabolites for biological testing on cell lines. Eur. J. Phar. Sci. 2005;24:539-43.
24.
Valencia-Islas NA, Zambrano A, Rojas JL. Ozone reactivity and free radical scavenging behavior of phenolic secondary metabolites in lichens exposed to chronic oxidant air pollution from Mexico City. J. Chem. Ecol. 2007;33:1619-34. [PubMed ID: 17619930].
25.
Russo A, Caggia S, Piovano M, Garbarino J, Cardile V. Effect of vicanicin and protolichesterinic acid on human prostate cancer cells: role of Hsp70 protein. Chem.Biol. Interact. 2012;195:1-10. [PubMed ID: 22063921].
26.
Ozenda P, Clauzade G. Les Lichens E´ tude Biologique et Flore Illustre´e. Editorial Masson et cie., Paris. 1970:801-82.
27.
Dobson FS. Lichens An illustrated guide to the British and Irish species. 4th ed. Slough: Richmond Publishing; 2000. p. 16-376.
28.
Brodo IM, Sharnoff SD, Sharnoff S. Lichens of North America. New Haven: Yale University Press; 2001. 795 p.
29.
Lin J, Opoku AR, Geheeb-Keller M, Hutchings AD, Terblanche SE, Jager AK, van Staden J. Preliminary screening of some traditional zulu medicinal plants for anti-inflammatory and anti-microbial activities. J. Ethnopharmacol. 1999;68:267-74. [PubMed ID: 10624887].
30.
Speit G, Haupter S. On the mechanism of differential giemsa staining of bromodeoxyuridine substituted chromosomes II Differences between the demonstration of sister chromatid differentiation and replication patterns. Human Gent. 1985;70:126-9.
31.
Oh HT, Kim SH, Choi HJ, Chung MJ, Ham SS. Antioxidative and antimutagenic activities of 70% ethanol extract from masou salmon (Oncorhynchusmasou). Toxicol. In Vitro. 2008;22:1484-8. [PubMed ID: 18682318].
32.
Yu Z, Xu M, Santana-Rios G, Shen R, Izquierdo-Pulido M, Williams DE, Dashwood RH. A comparison of whole wheat, refined wheat and wheat bran as inhibitors of heterocyclic amines in the Salmonella mutagenicity assay and in the rat colonic abberant crypt focus assay. Food Chem. Toxicol. 2001;39:655-65. [PubMed ID: 11397513].
33.
Mortelmans K, Zeiger E. The Ames Salmonella/ microsome mutagenicity assay. Mutat. Res. 2000;455:29-60. [PubMed ID: 11113466].
34.
Mortelmans K, Riccio ES. The bacterial tryptophan reverse mutation assay with Escherichia coli WP2. Mutat. Res. 2000;455:61-9. [PubMed ID: 11113467].
35.
Orhan F, Baris O, Yanmis D, Bal T, Guvenalp Z, Gulluce M. Isolation of some luteolin derivatives from Mentha longifolia (L) Hudson subsp longifolia and determination of their genotoxic potencies. Food. Chem. 2012;135:764-9. [PubMed ID: 22868156].
36.
Gulluce M, Agar G, Baris O, Karadayi M, Orhan F, Sahin F. Mutagenic and antimutagenic effects of hexane extract of some Astragalus species grown in the Eastern Anatolia region of Turkey. Phytother. Res. 2010;24:1014-8. [PubMed ID: 19957249].
37.
Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin. Chem. Lab. Med. 1988;34:497-500.
38.
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976;72:248-54. [PubMed ID: 942051].
39.
Anderson IB, Mullen WH, Meeker JE, Khojasteh-Bakht SC, Oishi S, Nelson SD, Blanc PD. Pennyroyal toxicity: Measurement of toxic metabolite levels in two cases and review of the literature. Ann. Inter. Med. 1996;124:726-34.
40.
Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 1967;70:158-69. [PubMed ID: 6066618].
41.
Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979;95:351-8. [PubMed ID: 36810].
42.
Al-Qurainy F, Khan S. Mutagenic effects of sodium azide and its application in crop improvement. World. App. Sci. J. 2009;6:1589-601.
43.
Ferguson LR, Denny WA. Genotoxicity of noncovalent interactions: DNA intercalators. Mutat. Res. 2007;623:14-23. [PubMed ID: 17498749].
44.
Hoffmann GR, Calciano MA, Lawless BM, Mahoney KM. Frameshift mutations induced by three classes of acridines lacZ reversion assay in Escherichia coli: potency of responses and relationship to slipped mispairing models. Environ. Mol. Mutagenesis. 2003;42:111-21.
45.
Guengerich FP, Johnsen WW, Ueng YF, Yamazaki H, Shimada T. Involvement of cytochrome P450, glutathione S-transferase and epoxide hydrolase in the metabolism of aflatoxin B1 and relevance to risk of human liver cancer. Environ. Health. Persp. 1996;104:557-62.
46.
Verma RJ. Aflatoxin Cause DNA Damage. Int. J. Hum. Genet. 2004;4:231-6.
47.
Sedmikova M, Reisnerora H, Dufkova Z, Burta I, Jilek F. Potential hazard of simultaneous occurrence of aflatoxins B1 and ochratoxin A. Vet. Med (Praha). 2001;46:169-74.
48.
Choi KC, Chung WT, Kwon JK, Jang YS, Yu JY, Park SM, Lee JC. Chemoprevention of a flavonoid fraction from Rhus verniciflua Stokes on aflatoxin B1-induced hepatic damage in mice. J. App. Microbiol. 2010;31:150-6.

comments